4.7 Article

Selectivity, Cocrystal Structures, and Neuroprotective Properties of Leucettines, a Family of Protein Kinase Inhibitors Derived from the Marine Sponge Alkaloid Leucettamine B

Journal

JOURNAL OF MEDICINAL CHEMISTRY
Volume 55, Issue 21, Pages 9312-9330

Publisher

AMER CHEMICAL SOC
DOI: 10.1021/jm301034u

Keywords

-

Funding

  1. Fonds Unique Interministeriel (FUI) PHARMASEA project
  2. Association France-Alzheimer (Finistere)
  3. CRITT-Sante Bretagne
  4. Fondation Jerome Lejeune
  5. Anna's Angels Down Syndrome Research Foundation
  6. Caroline Ball Family Fund
  7. Canadian Institutes for Health Research [1097737]
  8. Canada Foundation for Innovation, Genome Canada
  9. GlaxoSmithKline
  10. Pfizer
  11. Eli Lilly
  12. Novartis Research Foundation
  13. Ontario Ministry of Research and Innovation
  14. Wellcome Trust
  15. Takeda
  16. Cancer Research UK [14532] Funding Source: researchfish

Ask authors/readers for more resources

DYRKs (dual specificity, tyrosine phosphorylation regulated kinases) and CLKs (cdc2-like kinases) are implicated in the onset and development of Alzheimer's disease and Down syndrome. The marine sponge alkaloid leucetttamine B was recently identified as an inhibitor of DYRKs/CLKs. Synthesis of analogues (leucettines) led to an optimized product, leucettine L41. Leucettines were cocrystallized with DYRK1A, DYRK2, CLK3, PIM1, and GSK-3 beta. The selectivity of L41 was studied by activity and interaction assays of recombinant kinases and affinity chromatography and competition affinity assays. These approaches revealed unexpected potential secondary targets such as CK2, SLK, and the lipid kinase PIKfyve/Vac14/Fig4. L41 displayed neuroprotective effects on glutamate-induced HT22 cell death. L41 also reduced amyloid precursor protein-induced cell death in cultured rat brain slices. The unusual multitarget selectivity of leucettines may account for their neuroprotective effects. This family of kinase inhibitors deserves further optimization as potential therapeutics against neurodegenerative diseases such as Alzheimer's disease.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available